Incidence and Overall Survival of Malignant Ameloblastoma

Abstract

BackgroundMalignant ameloblastoma, comprising metastasizing ameloblastoma and ameloblastic carcinoma, represents 1.6–2.2% of all odontogenic tumors. Due to its rare nature, malignant ameloblastoma has only been reported in the literature in small case series or case reports. Using the Surveillance, Epidemiology and End-Results (SEER) database, we have performed a population-based study to determine the incidence rate and the absolute survival of malignant ameloblastoma.MethodUsing the International Classification of Diseases for Oncology (ICD-O) codes 9310/3 and 9270/3, data from the SEER database were used to calculate the incidence rate and absolute survival rate of population with malignant ameloblastoma.ResultsThe overall incidence rate of malignant ameloblastoma was 1.79 per 10 million person/year. The incidence rate was higher in males than females and also higher in black versus white population. The median overall survival was 17.6 years from the time of diagnosis and increasing age was associated with a statistically significant poorer survival.ConclusionsTo our best knowledge, we report the largest population-based series of malignant ameloblastoma. The incidence rate was 1.79 per 10 million person/year and the overall survival was 17.6 years.

Malignant peripheral ameloblastoma arising from the gingiva: A case report

“…[4] Additionally, malignant ameloblastomas, which can arise de novo or from a preexisting ameloblastoma, occur in 1.6%-2.2% of all ameloblastomas. [5] Ameloblastic carcinomas arising from peripheral ameloblastomas are exceedingly rare, with only approximately eleven cases of peripheral ameloblastic carcinoma having been reported to date, including one case of an initially benign appearing peripheral ameloblastoma recurring as ameloblastic carcinoma. [4,[6][7][8][9][10] Although there have been no prior studies demonstrating the relationship between non-Hodgkin lymphoma or radiation and the development of peripheral ameloblastoma, a retrospective study evaluating 322 non-Hodgkin lymphoma cases found a significantly increased risk for head and neck cancers among patients receiving radiation therapy for early-stage non-Hodgkin lymphoma.…”

“…[12,13] Peripheral ameloblastomas vary in size but are usually limited to the gingiva without invading the underlying bone. [5] Differential diagnosis includes peripheral giant cell granuloma, peripheral odontogenic fibroma, peripheral ossifying fibroma, papilloma, pyogenic granuloma, epulis, and fibroma. [13][14][15] Radiological examination may demonstrate superficial cortical bone erosion or depression, which are known as "cupping" or "saucerization".…”

Rare case of ameloblastoma with pulmonary metastases

“…MA represents 1.6-2.2% of all odontogenic tumors (8). There is one report, by Rizzitelli et al in 2014, on the incidence of MA and its survival rate (9). Unfortunately, that study did not calculate the rate of MA and AC separately; instead, they were calculated as a single percentage.…”

“…The overall survival rate is 17.6 years -despite being metastatic, the disease has an indolent course. The peak incidence is between the third and fifth decade (9).…”

Ameloblastic carcinoma of the maxilla: A case report and an updated review of the literature

“…Malignant odontogenic tumors with the histological features of ameloblastoma represent 1.6–2.2% of all odontogenic tumors (1), and may be classified as metastasizing ameloblastoma or ameloblastic carcinoma (AC); it is generally agreed that the term ‘malignant ameloblastoma’ refers to tumors exhibiting features of a benign ameloblastoma, while the term ‘ameloblastic carcinoma’ indicates tumors that are still recognizable as ameloblastoma but possess histological features of malignancy. AC, which seems to be more frequent than malignant ameloblastoma (2), is considered to be a rare tumor, as few cases have been published.…”